<DOC>
	<DOCNO>NCT00422981</DOCNO>
	<brief_summary>The purpose study find different dos Investigational Drug safe , tolerable , effect Mild Cognitive Impairment ( MCI ) .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study Evaluate Subjects With Mild Cognitive Impairment</brief_title>
	<detailed_description>Pre-Clinical experiment indicate AL-108 compound neuroprotective , cognitive protective neurotrophic property ; therefore , compound could test variety human disease . Human diseases include Cognitive impairment associate age neurodegenerative disease Alzheimer 's Disease . This clinical trial aim provide dose rationale well safety tolerability information AL-108 evaluate 12 week intranasal administration subject Mild Cognitive Impairment ( MCI ) . There currently drug approve treatment MCI accept treatment standard treatment approach .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Is male female , 5585 year age ( inclusive ) screen Selfreported memory complaint , corroborate spouse companion appropriate . Wechsler Memory Scale III ( WMSIII ) ageadjusted Logical Memory II score ≤ 5 . MiniMental State Exam ( MMSE ) ≥24 . Center Epidemiologic StudiesDepression ( CESD ) score &lt; 27 . Normal thyroid function , define TSH , T3 T4 within normal limit . Agree consume alcoholic beverage within 8 hour study visit . Willing able sign inform consent complete CTB test procedure list protocol . Fluently read speaks English . Female subject must surgically sterile postmenopausal least 2 year . If &lt; 2 year postmenopausal , follicle stimulate hormone ( FSH ) ≥40 mIU/mL must obtain . Subjects significant , untreated psychiatric illness CNS condition ( schizophrenia , Parkinson 's disease , stroke , etc . ) could interfere study evaluation procedure pose additional risk . Subjects history uncomplicated depression may participate remission stable dose antidepressant medication least 2 month . History significant head trauma follow persistent neurologic default know structural brain abnormality . History alcohol substance abuse dependence within past year . Acute infective sinusitis . History presence abnormality external internal structure nose nasopharynx , except surgical correction nasal septum `` broken nose '' least 2 year previously , surgical repair cleft palate &lt; 30 year age . Use medication know cause frank obtundation cognition Use approve investigational medication Alzheimer 's Disease within 3 month screen History current significant systemic disease judge interfere study evaluation likely safety concern . Untreated sleep apnea treatment sleep apnea &lt; 3 month . Abnormal clinical laboratory test result , specifically : Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2 х upper limit normal ( ULN ) , Hematology &lt; 80 % low limit normal , Creatinine ≥2 mg/dL , Other clinical laboratory value vital sign consider clinically significant opinion Investigator . Treatment investigational drug , biologic , device within previous 30 day prior screen . Surgery involve general anesthesia within past 3 month plan surgery require general anesthesia study period .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Memory</keyword>
	<keyword>Alzheimers</keyword>
	<keyword>Cognition</keyword>
	<keyword>Mind</keyword>
	<keyword>Aging</keyword>
</DOC>